cryptotanshinone has been researched along with Pulmonary Disease, Chronic Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Deng, D; Fu, Y; Huang, R; Tang, P; Wan, Y; Xie, T; Zheng, Y | 1 |
| Chen, J; Dai, Y; Jiang, L; Li, Z; Liu, P; Song, H; Wang, Y; Yang, W | 1 |
2 other study(ies) available for cryptotanshinone and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Cryptotanshinone Reverses Corticosteroid Insensitivity by Inhibition of Phosphoinositide-3-Kinase-δ in Chronic Obstructive Pulmonary Disease.
Topics: Adrenal Cortex Hormones; Dexamethasone; Histone Deacetylase 2; Humans; Leukocytes, Mononuclear; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phosphatidylinositols; Proto-Oncogene Proteins c-akt; Pulmonary Disease, Chronic Obstructive | 2023 |
Cryptotanshinone alleviates lipopolysaccharide and cigarette smoke-induced chronic obstructive pulmonary disease in mice via the Keap1/Nrf2 axis.
Topics: Animals; Cigarette Smoking; Glutathione; Humans; Kelch-Like ECH-Associated Protein 1; Lipopolysaccharides; Lung; Mice; NF-E2-Related Factor 2; Nicotiana; Pulmonary Disease, Chronic Obstructive | 2023 |